| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. | J Clin Oncol | 2009 | 2.32 |
| 2 | Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice. | J Clin Invest | 2011 | 1.91 |
| 3 | Case studies showing clinical signs and management of cutaneous toxicity of the MEK1/2 inhibitor AZD6244 (ARRY-142886) in patients with solid tumours. | Acta Oncol | 2010 | 0.80 |